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INTRODUCTION
Blood-derived progenitor cells are being used incre a s-
ingly as an alternative to bone marrow (BM) as a source of
stem cells for human auto- and allografting [1–3]. The use
of hematopoietic growth factors is essential to increase the
number of circulating progenitors in the peripheral blood in
o rder to allow rapid and efficient collection of stem cells
f rom normal donors [1–4]. For this purpose, Filgrastim, a
granulocyte colony-stimulating factor (G-CSF), has been
used in most of the published allograft studies as the growth
factor of choice [3–6]. The use of such G-CSF mobilized
progenitor cells (MoPBSC) for infusion into myelo-ablated
recipients has resulted in consistent and rapid engraftment.
The number of T cells in a typical G-CSF mobilized
peripheral blood graft (MoPBSC), however, is up to 10-fold
higher than in an average BM graft [1,3–8]. This observ a t i o n
raises the possibility that MoPBSC would be associated with
a higher risk of graft-vs.-host disease (GVHD) than bone-
m a rrow allografts [8,9]. Clinical data do suggest an incre a s e d
incidence for the chronic variant of GVHD [3,7–10]. Deplet i o n
of T cells from bone marrow grafts has been successful in
d e c reasing the incidence and severity of GVHD, both in
matched and mismatched allografts [11–13].
C o u n t e rflow centrifugal elutriation (CCE) separates cells
a c c o rding to size and, to a much lesser degree, density [14].
This technique has been used very successfully to remove T
lymphocytes in clinical BM allografting [15–18]. CCE-
p rocessed BM cells have been re p o rted to be enriched for
assayable hematopoietic progenitor cells (HPC), but it has
also been re p o rted that the re c o v e ry of very early HPC (e.g.,
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ABSTRACT
Blood-derived progenitor cells obtained following mobilization with granulocyte colony-stimulating factor (MoPBSC)
a re increasingly being used as an alternative to bone marrow (BM) in allogeneic stem cell transplantation. The higher
numbers of mature T lymphocytes in MoPBSC grafts may increase the risk of (chronic) graft-vs.-host disease. Counterflo w
centrifugal elutriation (CCE) is an effective method for T-cell depletion of BM grafts. The elutriation characteristics of
steady-state BM and MoPBSC were compared using a CCE pro c e d u re in which fractions were obtained after small
i n c remental increases in flow rate with constant centrifugal force. Counterflow centrifugal elutriation experiments with
MoPBSC from six healthy volunteers showed that 54% of all cells collected were re c o v e red in the #15 mL/minute fract i o n s ,
w h e reas experiments with mononuclear BM cells from five healthy volunteers resulted in re c o v e ry of 52% of collected
cells from the $19 mL/minute fractions. The peak concentrations of CD341 cells were found in the same fraction (18
mL/minute), but more CD341 cells from MoPBSC were re c o v e red from the small (#16 mL/minute) fractions (54% for
MoPBSC, 26% for BM; p = 0.08). The small CD341 cells from BM were more frequently lacking CD38 and human leu-
cocyte antigen-DR expression than the small CD341 cells from MoPBSC. Mature T-cells (CD31) in BM and MoPBSC
samples had similar CCE features, as did early (long-term culture initiating cells, high-proliferative potential colony-
f o rming cells) and more mature (colony-forming units granulocyte/macrophage, BFU-e) hematopoietic pro g e n i t o r
cells. The results of this study suggest that T-cell depletion by CCE of MoPBSC as compared to BM products, may lead
to a greater loss of CD341 cells, but not of immature hematopoietic progenitor cells.
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l o n g - t e rm culture initiating cells [LTC-IC]) may be poor
c o m p a red to more mature HPC (e.g., colony-forming units
g r a n u l o c y t e / m a c rophage [CFU-GM]) [19–21]. We postulat-
ed that the use of MoPBSC depleted of T cells via CCE
might be an attractive method to decrease the risk of severe
GVHD after transplantation. In this study, the elutriation




Donors for this study were healthy paid volunteers who
donated either BM or mobilized peripheral blood compo-
nents. All had given informed consent according to guidelines
established by the Institutional Review Board of the
Methodist Hospital of Indiana. Bone marrow samples of
50–70 mL were aspirated from the posterior iliac crest and
collected into heparin. Peripheral blood cells were collected
by leukapheresis with a COBE Spectra on day 5, following
four daily s.c. injections of G-CSF (Neupogen, Thousand
Oaks, CA) 10 mg/kg. MoPBSC were collected into acid-
c i tr a t e - d e x t rose-A. Typical collections processed a volume
equal to two times blood volume, or a total of 10L.
L e u k ocyte separation and red-cell depletion f o r
M o P B S C
The collected MoPBSC were diluted with calcium- and
m a g n e s i u m - f ree Hanks’ balanced salt solution (HBSS)
(Whittaker, Walkersville, MD) and centrifuged at 400 g for
5 minutes. The supernate was then removed and replaced by
red-cell lysing solution (0.1% KHCO3, 0.85% NH4Cl) for
5 minutes. The cells were washed twice in HBSS and re s u s-
pended in 20–40 mL of HBSS with 2% fetal bovine seru m
(FBS) (Hyclone, Logan, UT). Samples of this suspension
w e re then diluted in Isoton II Diluent (Coulter Diagnostics,
Hialeah, FL) and counted with a Coulter CBC5 cell counter.
M o n o n uclear cell separation for BM
BM samples were diluted five times with Ca- and Mg-f re e
HBSS. Mononuclear cells were isolated by density gradient
centrifugation (340 g for 20 minutes) over Ficoll-Hypaque
(1.077 g/dl; Pharmacia, Piscataway, NJ). Cells were then
washed once with HBSS and resuspended in 20–40 mL
HBSS with 2% FBS. Samples were taken for cell counts.
C o u n t e r f l o w centrifugal elutriation pr o c e d u r e
Cell suspensions were loaded into a Beckman JE-5.0 elut r i-
ation rotor with a 4-mL standard chamber (Beckman Instru-
ments, Palo Alto, CA) after sterilization by autoclaving ( 1 2 1 ° C
for 20 minutes). Loading was perf o rmed at 18°C with a flow r a t e
of 5 mL/minute and a rotor speed of 2600 rpm (relative cen-
trifugal force 651–946 g). The elutriation medium was 0.9%
Sodium Chloride Injection USP (Baxter, Deerfield, IL). A
M a s t e rflex peristaltic pump (Cole-Parmer Instrument, Bar-
rington, IL) was used to maintain a constant and precise flo w
rate. After the cells had been loaded into the chamber, the
rotor speed was decreased to 2300 rpm (510–741 g). Subse-
q u e n t l y, the flow rate was slowly increased to 14 mL/minute
with rotor speed held constant. A volume of 50 mL was elut-
ed. Then stepwise, the flow rate was increased incre m e n t a l l y
by 1 mL/minute, and volumes of 50 mL were collected at 15, 1 6 ,
17, 18, 19, 20, 21, 22, and 23 mL/minute. Finally, the ro t o r
was turned off and the remaining cells were eluted (R/O frac-
tion). The cells collected in each fraction were centrifuged
and resuspended in phosphate-buff e red saline (PBS) with 2%
FBS and 1 mM ethylene diamine tetraacetic acid (EDTA ) .
M e t h ylcellulose assa y s
Cells fractionated by CCE, or cells obtained from long-
t e rm cultures were plated in 35-mm petri dishes (Corn i n g ,
Cambridge, MA) in a total volume of 1 mL standard methyl-
cellulose complete medium containing 0.9% methylcellulose,
30% FBS, 1% bovine serum albumin, 100 mmol/L 2-merc a p-
toethanol, 3 U/mL ery t h ropoietin, 2 mM L-glutamine, and
5% phyto-hemagglutinin treated leukocyte conditioned
medium (StemCell Technologies, Va n c o u v e r, British Colum-
bia, Canada). All cultures were incubated at 37°C in fully
h u m i d i fied air with 5% CO2. At 14 days, cultures were start-
ed in duplicate and scored with an inverted microscope for
the presence of ery t h roid bursts (BFU-e), GM colonies
(CFU-GM), and mixed-cell colonies (CFU-GEMM). BFU-e
(containing .200 cells) were identified on the basis of their
o r a n g e - red color. Colonies of .50 nonery t h roid cells were
s c o red as GM colonies. Colonies containing .200 cells com-
posed of both ery t h roid and nonery t h roid elements were
s c o red as mixed-cell colonies. High-proliferative potential
c o l o n y - f o rming cells (HPP-CFC) were scored after 28 days
in culture, and were distinguishable as large (.0.5 mm and
f requently up to 3 mm in diameter), dense, late-appearing
colonies which were composed primarily of granulocytes and
a smaller number of monocytes.
Long-term culture initiating cells
As described, Stroma-noncontact cultures were used to
assay for long-term culture initiating cells (LTC-IC) [20].
S t romal layers, which consisted of 131 05 cells and were
derived from the R/O fraction of the same donor, were put in
the upper well of 24-well transwell plates (0.4 m- p o re polycar-
bonate membrane; Costar, Cambridge, MA). 131 05 f r a c t i o n-
ated cells were plated in the bottom wells of the transwell
plates. No cytokines were added to the long-term culture
complete media (StemCell Technologies), which consisted of
alpha-minimum essential medium with 12.5% FBS, 12.5%
horse serum, 10– 4M 2-mercaptoethanol, 2mM L-glutamine,
0.2mM i-inositol, 20mM folic acid, and 10– 6M water soluble
h y d ro c o rtisone. The cultures were maintained in fully
h u m i d i fied air at 37°C and 5% CO2 for 5 weeks. At weekly
i n t e rvals the cultures were fed by removing half of the cell-f re e
s u p e rnatant from the top or bottom wells and replacing with
f resh complete media. Nonadherent cells were re c o v e re d
f rom the bottom wells after 5 weeks and were assayed in the
CFU-GM assay for the presence of LT C - I C .
F l o w cytometry studies
The FACStar Plus flow cytometer (Becton Dickinson,
San Jose, CA) equipped with an argon laser with emission
at 488 nm was used. Data acquisition was accomplished
with the Lysys 2.0 software package after gating of cell
populations defined by their light-scatter characteristics. A
minimum of 20,000 events were analyzed for each sample.
For surface antigen detection, cells were washed once with
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PBS (containing 2% FBS and 1mM EDTA), and re s u sp e n d e d
to 5–1031 06 cells/mL in PBS. 100 mL cells were pelleted
and 10 mL of the appropriate antibody was added. After
incubation for 30 minutes in the dark at 4°C, the cells were
washed twice with PBS, fixed with 1% p a r a f o rmaldehyde, and
analyzed for fluorescence. The antibodies used were :
CD34-PE, CD3-PE, CD11b-PE, CD15-FITC, IgG1-PE, and
I g G1-FITC (Becton Dickinson), CD38-FITC, HLA-DR-TC,
and IgG1-TC (Caltag, South San Francisco, CA).
Statistical anal y s i s
The statistical significance of data obtained was tested with the
two-tailed t-test. p-values of ,0.05 were considered s i g n i fic a n t .
RESULTS
Nonfractionated samples and cell loss during CCE
Five volunteers, between the ages of 21 and 30 years,
donated bone marrow for this study. Six diff e rent volun-
teers, between the ages of 20 and 32 years, donated G-
CSF mobilized peripheral blood. The mononuclear BM
cells contained 65.4 6 5.2% lymphocytes and 28.3 6
3.4% myeloid/monocytic cells; the MoPBSC pro d u c t s
contained 66.2 6 4.3% lymphocytes and 33.8 6 3 . 8 %
myeloid/monocytic cells. These 11 specimens were sub-
jected to the CCE pro c e d u re as described in Methods.
The re c o v e ry rates for BM and MoPBSC cells were not
significantly diff e rent (p 5 0.68). About one third of the
loaded cells were lost during the CCE pro c e d u re with
recoveries ranging from 37 to 85%. Because of this cell
loss, all further results were expressed as percentages of
total cells collected.
Elutriation pr o f i l e s
BM and MoPBSC were subjected to CCE with a con-
stant centrifugal force (2300 rpm) and an increasing counter-
flow rate with incremental steps of 1 mL/minute. Fractions
were obtained at each mL/minute interval between #14 and
23 mL/minute; subsequently an R/O fraction was obtained.
In the BM group, 17 6 3% (mean 6 SE) of all cells were
collected in the #14 mL/minute fraction, a similar perc e n tage
in the 15 mL/minute fraction, and 34 6 7% in the R/O
fraction. Each of the other eight fractions contained only
3.1 to 5.8% of the total cells collected. In contrast, more
cells were collected in the smaller cell fractions from the
MoPBSC group: 49 6 9% of the cells were obtained from
the #15 mL/minute fractions, and fewer in the R/O frac-
tion (21 6 11%). Again, fractions 16–23 each contained
only between 2.2 and 7.1% of all cells collected.
Distribution of CD34 1 c e l l s
BM cells loaded into the CCE centrifuge contained 3.3 6
0.5% (mean 6 SE) CD341 cells, whereas MoPBSC con-
tained only 1.5 6 0.5% CD341 cells. After elutriation, the
BM cells were enriched for CD341 cells in fractions 16–21,
and depleted in fractions #14 and 15. The peak concentra-
tion of CD341 cells was found in fraction 18 mL/minute.
With MoPBSC, enrichment for CD341 cells occurred in
fractions 17–20; the peak in fraction was again found in frac-
tion 18 mL/minute. When c o n c e n t r a t i o n s of CD341 cells were
c o m p a red, no clear diff e rences in elutriation pattern were
o b s e rved between BM and MoPBSC. When the total numbers
of CD341 cells per collected fraction were considered, howe v e r,
C D 3 41 cells from MoPBSC were elutriated, on average, at a
lower counterflow rate than CD341 cells from BM (Fig. 1 ) .
Figure 1. CD34 1 cells collected from each elutriation fraction
Results are expressed as percentages of total collected CD341 cells. Bars indicate SE.
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The number of CD341 cells from fractions #16 mL/minute,
as a percentage of all CD341 cells collected, was greater for
MoPBSC than for BM (54% vs. 26%), although the diff e r-
ence did not reach significance (p 5 0 . 0 8 ) .
Unseparated BM and MoPBSC samples were double-
stained for CD34 and CD38, and for CD34 and HLA-DR.
Among the CD341 cells from BM, 1.24 6 0.38% were
C D 3 8– (mean 6 SE) and 11.9 6 2.3% were HLA-DR–;
among unseparated MoPBSC CD341 cells, 5.6 6 2.4% were
C D 3 8–, and 11.2 6 1.6 % were HLA-DR–. Following elutria-
tion, BM and MoPBSC showed similar patterns, with enrich-
ment of CD341/ C D 3 8– and CD341/ D R– cells in the low
flow-rate fractions (#18 mL/minute), and pro g ressive deple-
tion of such cells from the larger cell fractions (Fig. 2).
Among the smaller cells (fractions #18 mL/minute), BM had
a significantly higher pro p o rtion of CD341C D 3 8– cells than
MoPBSC (p , 0.03). The same was true for CD341D R– c e l l s
(p 5 0 . 0 5 ) .
Distribution of CD3 1 c e l l s
The CD3 antigen was used as a marker for mature T
lymphocytes in the various stem cell products. Mononuclear
BM contained 20.0 6 2.6% and MoPBSC contained 43.3 6
6.3% CD31 cells. After elutriation, BM cells showed enrich-
ment (in concentration) of CD31 cells in the #14, 15
mL/minute (peak) and 16 mL/minute fractions, and pro g re s-
sive depletion in the larg e r-cell fractions. MoPBSC showed a
similar pattern of enrichment in fractions #14,15 m L / m i n u t e
(peak) and 16 mL/minute, and pro g ressive depletion beyond
the 18 mL/minute fraction. When total numbers of collected
Figure 2. Populations of CD34 1CD38- and CD34 1DR- cells in each elutriation fraction
Results are expressed as the ratios of CD341C D 3 8– vs CD341C D 3 81 and CD341D R– vs. CD341D R1 cells. In each case the ratio of the cells loaded was
a r b itrarily set to be 1. Bars indicate SE.
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C D 31 cells were considered, the cumulative depletion curv e s
for BM and MoPBSC were virtually superimposable (Fig. 3).
M a t u r e myeloid cells
F l u o rescence for the combination CD151C D 1 1 b1 w a s
used as a marker for mature myeloid cells. The BM mononu-
clear cells loaded into the elutriation chamber contained 34.4
6 4.7%, whereas the MoPBSC specimens contained 26.8 6
5.9% CD151C D 1 1 b1 cells. After elutriation, pro g re s s i v e
enrichment occurred in BM fractions $18 mL/minute and
MoPBSC fractions $17 mL/minute. The cumulative
d e p l etion of CD151C D 1 1 b1 cells proceeded more rapidly
with MoPBSC than with BM (Fig. 3).
Hematopoietic progenitor cells
For this study we added the numbers of BFU-e, CFU-GM,
and CFU-GEMM to arrive at the number of “more
m a t u re” myeloid progenitor cells (colony-forming cells
[CFC]). HPP-CFC and LTC-IC were used to quantify early
progenitor cells. The concentration of CFC in the BM and
MoPBSC specimens loaded into the elutriation chamber
was 488 6 89 and 246 6 64 (mean 6 SE per 105 c e l l s ) ,
re s p e c t i v e l y. After elutriation, both the BM and MoPBSC
specimens showed increased CFC concentrations in the 16–20
mL/minute fractions. When the total numbers of CFC
c o llected were studied, MoPBSC samples appeared to have
a larger proportion of CFC in the smaller-cell fractions (#
16 mL/minute) than BM samples (Table 1; Fig. 3). The
d i fference, however, was not significant (p 5 0.21).
HPP-CFC were more frequent in the BM specimens
(16.3 6 5.5 per 105 cells) than in the MoPBSC samples (5.1
6 2.6 per 105 cells). The elutriation profiles for BM and
MoPBSC were very similar with enrichment in the 16–18
mL/minute fractions for BM, and the 17–20 mL/minute
fractions for MoPBSC. Cumulative depletion profiles for
BM and MoPBSC were superimposable (Fig. 3).
LTC-IC were clearly more frequent in the BM samples
(43.3 6 35.6 per 105 cells) than in MoPBSC samples (1.8 6
1.3 per 105 cells). Enrichment in c o n c e n t r a t i o n was found for
BM in the 15–19 mL/minute fractions, and for MoPBSC in
the 15–18 mL/minute fractions. Cumulative depletion pro fil e s
for BM and MoPBSC were, again, superimposable (Fig. 3).
DISCUSSION
This study confirms results previously obtained by several
g roups demonstrating that CCE is capable of subdividing
C D 3 41 cells from BM on the basis of the CD341 cell matur a t i o n
Figure 3. Cumulative depletion of various cell populations during the elutriation process
Bars indicate SE.
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level. Small CD341 cells appear more likely to be CD38 nega t i v e
or HLA-DR negative, or both [20,22,23], and more capable
of forming early hematopoietic colonies such as HPP-CFC
and LTC-IC [22–26]. The current study found a pattern
quite similar to BM for G-CSF mobilized PBSC fro m
healthy volunteers. The smallest CD341 cells from MoPBSC
a p p e a red to be the most immature. Additionally, CD341 c e l l s
f rom MoPBSC and those from steady-state BM appeared to
peak in the same flow-rate fraction (fraction 18 mL/minute,
Fig. 1). The distributions of CD341 C D 3 8– and CD341D R–
subpopulations were also quite similar (Fig. 2).
F u rt h e rm o re, the various elutriation fractions of BM
and MoPBSC contained pro p o rtionate numbers of CFC.
More specifically, the number of HPP-CFC was somewhat
higher in BM than MoPBSC, but the distribution over the
various elutriation fractions was similar (Fig. 3). The LT C -IC
concentration was markedly higher in BM than in MoPBSC;
however, the distributions over the various elutriation frac-
tions were again similar (Fig. 3). These LTC-IC results are
in partial disagreement with studies by other gro u p s
[27–29]. Pettengell et al. found more LTC-IC in leuka-
pheresis products obtained after mobilization with chemo-
therapy and G-CSF than in steady-state BM [27]. Prosper et
al. noted a 59-fold increase in the concentration of LTC-IC
in leukapheresis products mobilized with G-CSF [28]. Two
possible explanations can be off e red for this apparent dis-
c re p a n c y. Major diff e rences exist in the methodology for
LTC-IC detection. In the studies cited, identical feeder lay-
ers were used for BM and MoPBSC [27–29]. In the current
study, cells from the R/O fractions were used as feeder cells.
The R/O fraction cells from MoPBSC may support the pro-
liferation of LTC-IC more poorly than those from BM.
Also, there may be diff e rences in the LTC-IC themselves.
P rosper et al. showed that LTC-IC from MoPBSC mobi-
lized with G-CSF, many had a limited proliferation poten-
tial [28,29]. These LTC-IC were often found in the
CD341/DR1 cell fraction, and were capable of maintaining
hematopoiesis for 5, but not 8, weeks [28]. A much smaller
p ro p o rtion of LTC-IC are found in the CD341/ D R– c e l l
fraction. These LTC-IC are able to maintain hematopoiesis
for 8 weeks, and are more comparable to LTC-IC fro m
steady-state BM [29].
Our study shows that CD341 cells from steady-state BM
and G-CSF–mobilized PBSC from healthy volunteers have
similar elutriation characteristics. One notable diff e rence is
that CD341 cells from MoPBSC appear to have a somewhat
smaller average size than CD341 cells from BM (Fig. 1).
These findings are in contrast with findings obtained by our
g roup when studying PBSC from breast cancer patients
f o llowing mobilization with the combination of cyclophos-
phamide, VP-16, and G-CSF [22]. The latter CD341 c e l l s
a p p e a red to be, on average, larger than those from norm a l
BM and, in general, had functional features of more mature
p rogenitors [22]. Furt h e rm o re, PBSC mobilized with
chemotherapy and G-CSF had higher concentrations of
various progenitor cells than normal BM, whereas in the cur-
rent study, PBSC mobilized with G-CSF alone appeared to
have the same or lower numbers of progenitor cells than
n o rmal BM. This observation confirms studies showing that
mobilization with chemotherapy and G-CSF results in
p h e resis products richer in CD341 and clonable pro g e n i t o r
cells than mobilization with G-CSF alone [1, 30,31]. To et al.
found that CD341 cells mobilized with G-CSF were more
f requently CD38– than were CD341 cells mobilized with
chemotherapy plus G-CSF [32]. This finding is compatible
with the cells’ elutriation characteristics, attesting to their
smaller size observed in the current study (Fig. 2) [22, 23].
M a t u re T cells, defined as CD31 cells, are elutriated at
low flow-rates, which has been the basis for the clinical use of
elutriation pro c e d u res for T-cell depletion of bone marro w
[15–19]. Previous studies demonstrated that early pro g e n i t o r
cells, such as HPP-CFC and LTC-IC, are elutriated at lower
flow rates than more mature progenitor cells (e.g., CFU-GM)
and the bulk of CD341 cells [20,21]. Consequently, T- c e l l
depletion by elutriation may lead to an even more extensive
loss of early progenitor cells than estimated by the loss of
C D 3 41 cells or CFU-GM, which are commonly used as
c l i nical parameters [21]. The current study suggests that the
same risk exists for MoPBSC. If the experimental method for
this study were used to remove 96% of CD31 cells fro m
MoPBSC products, then 63% of CD341 cells and CFC, but
85% of LTC-IC, would be lost (Fig. 3). Similarly, if 96% of
C D 31 cells were removed from BM products, 42% of
C D 3 41 cells, 49% of CFC, and 83% of LTC-IC would be
removed. The loss of LTC-IC appears to be similar for T- c e l l
depletion of MoPBSC and BM by this elutriation method,
but the loss of more mature progenitor cells may be more
p ronounced for MoPBSC. Assuming BM and MoPBSC
p roducts each contain 531 06 C D 3 41 cells/kg, and aiming at
96% T-cell depletion for both, the final products for infusion
would contain quite diff e rent numbers of T cells. The fin a l
MoPBSC product would contain 1.831 06 C D 3 41/ k g ,
2 . 131 08/kg nucleated cells, and 5.731 06/kg CD31 cells. The
final BM graft would also contain 1.831 06 C D 3 41/kg, but
only 0.4531 08/kg nucleated cells and 0.831 06/kg CD31 c e l l s .
Other T-cell depletion strategies for MoPBSC, such as
positive selection of CD341 cells or depletion of lympho-
cytes with the CAMPATH I monoclonal antibody, have led
to similar losses of CD341 cells [33]. Despite the rapid
expansion in the use of allogeneic PBSC, a significant risk
for loss of early progenitor cells during elutriation pro c e-
dures and other T-cell depletion remains. Relative risks and
benefits must be weighed for each method in selecting a
clinical strategy. It should be appreciated, however, that
C D 3 41 cell numbers, and even CFC, are inadequate surrogate
Table 1. Number of CFC in the various elutriation fractions as percentage of
total CFC collected
Fraction BM MoPBSC
,14 mL/minute 1.3 6 0.7* 16.8 6 8.1
15 11.3 6 5.3 18.4 6 6.0
16 10.8 6 2.1 16.8 6 5.0
17 11.3 6 1.2 10.9 6 1.8
18 14.8 6 2.3 7.4 6 1.8
19 11.2 6 2.1 6.6 6 2.6
20 8.1 6 1.0 7.1 6 3.0
21 5.1 6 1.0 6.4 6 4.2
22 5.3 6 1.0 3.4 6 1.8
23 3.8 6 0.6 1.3 6 0.6
R/O 17.2 6 2.5 5.0 6 2.2
*Mean 6 standard error (SE).
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markers for the true hematopoietic stem cell, and that the
contributions of various subsets of these surrogate markers
on early and late engraftment still need to be ascertained in
clinical allogeneic transplantation.
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